View ValuationGerresheimer 향후 성장Future 기준 점검 3/6Gerresheimer (는) 각각 연간 42.7% 및 5.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 46% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 7.7% 로 예상됩니다.핵심 정보42.7%이익 성장률46.04%EPS 성장률Life Sciences 이익 성장17.5%매출 성장률5.2%향후 자기자본이익률7.74%애널리스트 커버리지Good마지막 업데이트30 Apr 2026최근 향후 성장 업데이트공시 • Jul 11Gerresheimer AG Provides Revenue Guidance for the Second Half of 2025Gerresheimer AG provided revenue guidance for the second half of 2025. In the second half of 2025, Gerresheimer expects stronger growth again based on production ramp-ups and a good order intake, and anticipates organic revenue growth of 0 – 2% compared to the previous year.공시 • Jun 05+ 1 more updateGerresheimer AG Revises Earnings Guidance for the Financial Year 2025Gerresheimer AG revised earnings guidance for the financial year 2025. For the financial year, the company expects organic revenue growth to be 1% to 2% compared to the previous year (previously: 3% to 5%).공시 • Apr 11Gerresheimer AG Confirms Earnings Guidance for the Mid-Term of the Fiscal Year 2025Gerresheimer AG confirmed earnings guidance for the mid-term of the fiscal year 2025. For the mid-term, the company expects organic revenue growth 8% - 10% CAGR.공시 • Apr 11Gerresheimer AG Provides Earnings Guidance for the Year 2024 and 2025Gerresheimer AG provided earnings guidance for the year 2024 and 2025. For the year 2024, the company expects revenue growth of 5% to 10%.For the year 2025, the company expects revenue growth of 10% to 15%.공시 • Oct 06Gerresheimer AG Provides Earnings Guidance for Full Year 2023Gerresheimer AG provided earnings guidance for full year 2023. For the year, the company expects Organic revenue growth: at least 10% and Medium-term guidance (for group level, currency-adjusted), Organic revenue growth: at least 10%.공시 • Jul 06Gerresheimer Ag Provides Revenue Guidance for Full Year 2023Gerresheimer AG provided revenue guidance for full year 2023. For the year, the company expects Organic revenue growth: at least 10% and Medium-term guidance (for group level, currency-adjusted), Organic revenue growth: at least 10%.모든 업데이트 보기Recent updates공시 • Apr 11Gerresheimer AG(XTRA:GXI) dropped from Germany SDAX (Total Return) IndexGerresheimer AG has been dropped from the Germany SDAX (Total Return) Index공시 • Nov 22Gerresheimer AG Announces Supervisory Board ChangesKlaus Röhrig, co-founder and Co-Chief Investment Officer of the Active Ownership Group, has been appointed to the Supervisory Board of Gerresheimer AG until the next Annual General Meeting in June 2026. He succeeds Dr. Dorothea Wenzel, who made her position available to reflect the changed shareholder structure of the company in the composition of the Supervisory Board. With his appointment, Klaus Röhrig also assumes the duties of Dr. Dorothea Wenzel on the Audit Committee of Gerresheimer AG. Klaus Röhrig will stand for election to the Supervisory Board at the next Annual General Meeting on June 3, 2026. In total, four shareholder representatives will be up for election at the next Annual General Meeting of Gerresheimer AG’s co-determined Supervisory Board.공시 • Oct 16+ 3 more updatesGerresheimer AG to Report Fiscal Year 2025 Results on Feb 26, 2026Gerresheimer AG announced that they will report fiscal year 2025 results at 1:25 PM, Central European Standard Time on Feb 26, 2026공시 • Oct 14Gerresheimer Ag Announces Fda Grants Approval of Sq Innovation's Lasix®? OnyuGerresheimer announced that the US Food and Drug Administration (FDA) granted SQ Innovation approval for Lasix ONYU for treatment of edema in congestive heart failure. Lasix ONYU is a combination product consisting of a novel high-concentration formulation of the diuretic furosemide and the Gerresheimer on-body drug delivery device (infusor). It was developed to enable subcutaneous infusion of furosemide at home for selected patients, as prescribed by a clinician without the need for a healthcare professional to administer the drug. The cartridge-based infusor was designed and developed by Gerresheimer based on its proprietary infusor platform for subcutaneous drug delivery. Gerresheimer also manages production of the device as a full-service solution provider. First products of Lasix ONYU are expected to be available on the market already in 2025. The FDA's approval of the combination product demonstrates Gerresheimer's innovative strength and its strong partnership with customers, from product design to large-scale manufacturing. Device based on Gerresheimer's innovative micropump technology: The cartridge-based infus or was designed and developed by Ger Resheimer based on its proprietary infUSor platform for subcutaneous Drug delivery. The core technology is an innovative micropump which enables controlled, precise administration of a drug product according to a defined therapy regimen. Designed with patient comfort and the environment in mind The lightweight, compact device is patched onto the patient's body, making it comfortable for the patient to wear while the drug is gently infused. The reusable component, which is rated for delivery of 48 treatments with diuretic furosemides, is recyclable. Because only the disposable unit requires sterilization, radiation can be used instead of chemical sterilization, and no electronic components end up in medical waste. This two-component concept was developed in line with Gerresheimer's EcoDesign principles, which aim to increase product lifespan and reduce waste. Reducing total cost of care and improving patients' quality of life. The combination product Lasix ONYU also opens up possibilities to reduce the total cost of care. The two-component design results in a lower cost per treatment, because only the disposable part of the device needs to be replaced. Most importantly, the infusor allows for home treatment, reducing the length of hospital stay or avoiding the need for hospitalization for intravenous diuretic administration altogether. First products expected to be available already in 2025 In addition to Gerresheimer's role in design and development, Gerresheimer also manages production the device as a full- service solution provider. The disposable unit for the infusor is, for example, produced at the Gerresheimer facility in Wackersdorf, Germany, on a high-capacity semi-automated line. Production commenced earlier this year in anticipation of approval and first products are expected to be available before the end of the year.공시 • Oct 10+ 2 more updatesGerresheimer AG Appoints Hans-Norbert Topp as Head of Combined Moulded Glass Business UnitGerresheimer AG announced that as part of the integration of Bormioli Pharma into the Gerresheimer Group, Gerresheimer has already begun to establish the combined Moulded Glass business as a global, independent unit. Hans-Norbert Topp, an internationally experienced manager with a proven track record, has been appointed to head the business unit.공시 • Aug 22Active Ownership Wants Review at Gerresheimer After Taking StakeOn August 21, 2025, Active Ownership announced that it saw major potential for value creation at Gerresheimer AG and called for a strategic review. Active Ownership expressly welcomes the planned sale process for the moulded glass division and calls for a swift settlement in order to strengthen the Company's cash flow and reduce debt. Active Ownership also stated that further key measures should include additional portfolio optimization and the implementation of an efficiency programme, particularly through cost reductions in administration and business units. Active Ownership added that this would improve the return on the Company's sales by five percentage points, while also calling for the creation of a strategy committee to review all of the Company's ongoing projects.공시 • Jul 11Gerresheimer AG Provides Revenue Guidance for the Second Half of 2025Gerresheimer AG provided revenue guidance for the second half of 2025. In the second half of 2025, Gerresheimer expects stronger growth again based on production ramp-ups and a good order intake, and anticipates organic revenue growth of 0 – 2% compared to the previous year.공시 • Jun 06Asset Value Investors Calls for Changes at Gerresheimer AGOn June 5, 2025, Asset Value Investors Limited called upon Gerresheimer AG to take steps to restore its market value, a move partially supported by another top 30 investor. Asset Value Investors expressed its views that new financial leadership is needed to restore the Company's relationship and credibility with investors, it said in an open letter to the Company. Asset Value Investors also urged the Company to establish a capital allocation committee and exit its moulded glass business as soon as possible. Union Investment, which holds a 0.9% stake in the Company, said it backed the calls for new leadership and a sale of the moulded glass business but did not see a need for a capital allocation committee.공시 • Jun 05+ 1 more updateGerresheimer AG Revises Earnings Guidance for the Financial Year 2025Gerresheimer AG revised earnings guidance for the financial year 2025. For the financial year, the company expects organic revenue growth to be 1% to 2% compared to the previous year (previously: 3% to 5%).공시 • Apr 24Gerresheimer AG, Annual General Meeting, Jun 05, 2025Gerresheimer AG, Annual General Meeting, Jun 05, 2025, at 10:00 W. Europe Standard Time.공시 • Apr 11Gerresheimer AG Confirms Earnings Guidance for the Mid-Term of the Fiscal Year 2025Gerresheimer AG confirmed earnings guidance for the mid-term of the fiscal year 2025. For the mid-term, the company expects organic revenue growth 8% - 10% CAGR.공시 • Mar 13Warburg Pincus, KKR Consortium Reportedly in Talks to Buy GerresheimerA consortium consisting of Warburg Pincus LLC and KKR & Co. Inc. (NYSE:KKR) are in talks to acquire Gerresheimer AG (ETR:GXI), the German maker of packaging for drugs and cosmetics, according to people familiar with the matter. The private equity firms emerged as the frontrunner after they teamed up and other potential bidders including Bain Capital dropped, the people said, asking not to be identified discussing confidential information. The Warburg Pincus-KKR consortium is unlikely to offer a significant premium to Gerresheimer’s current price and there are still major hurdles to a deal, some of the people said. While the talks are advanced, any final agreement could take weeks and a deal could still fall apart, they added. Representatives for Gerresheimer, Warburg Pincus, KKR and Bain declined to comment.공시 • Feb 27Gerresheimer AG announces Annual dividend, payable on June 10, 2025Gerresheimer AG announced Annual dividend of EUR 1.2500 per share payable on June 10, 2025, ex-date on June 06, 2025 and record date on June 09, 2025.공시 • Feb 21Phillips-Medisize, Bain Capital Reportedly Eye GerresheimerUS medical solutions company Phillips-Medisize (Phillips-Medisize, LLC) and buyout firm Bain Capital (Bain Capital, LP) are among potential bidders for Gerresheimer AG (XTRA:GXI), the German maker of packaging for drugs and cosmetics, according to people familiar with the matter. The firms join other suitors that have been evaluating possible offers for part or all of Gerresheimer, the people said, asking not to be identified because the information is private.공시 • Feb 20Gerresheimer AG to Report Q3, 2025 Results on Oct 10, 2025Gerresheimer AG announced that they will report Q3, 2025 results on Oct 10, 2025공시 • Feb 11Gerresheimer Discussing Takeover with Private Equity InvestorsGerman pill bottles and syringes maker Gerresheimer AG (XTRA:GXI) said on February 07, 2025 that it is in early-stage talks with private equity investors over a potential takeover, confirming a media report. The private equity firms have expressed, on an informal and non-binding basis, their interest to explore a possible public takeover offer for Gerresheimer, the company said. The discussions are still in a very preliminary stage and it is not certain at this point whether an offer will actually be made, the firm added, without disclosing further details. The statement was made after news agency Bloomberg previously reported that private equity firms Warburg Pincus LLC, EQT AB (publ) (OM:EQT) and KKR & Co. Inc. (NYSE:KKR) among other suitors have shown interest in the German pill bottles and syringes maker.공시 • Apr 11Gerresheimer AG Provides Earnings Guidance for the Year 2024 and 2025Gerresheimer AG provided earnings guidance for the year 2024 and 2025. For the year 2024, the company expects revenue growth of 5% to 10%.For the year 2025, the company expects revenue growth of 10% to 15%.공시 • Dec 06+ 1 more updateGerresheimer AG, Annual General Meeting, Jun 05, 2024Gerresheimer AG, Annual General Meeting, Jun 05, 2024.공시 • Oct 06Gerresheimer AG Provides Earnings Guidance for Full Year 2023Gerresheimer AG provided earnings guidance for full year 2023. For the year, the company expects Organic revenue growth: at least 10% and Medium-term guidance (for group level, currency-adjusted), Organic revenue growth: at least 10%.공시 • Sep 28+ 2 more updatesGerresheimer AG to Report Q2, 2024 Results on Jul 11, 2024Gerresheimer AG announced that they will report Q2, 2024 results on Jul 11, 2024공시 • Jul 06Gerresheimer Ag Provides Revenue Guidance for Full Year 2023Gerresheimer AG provided revenue guidance for full year 2023. For the year, the company expects Organic revenue growth: at least 10% and Medium-term guidance (for group level, currency-adjusted), Organic revenue growth: at least 10%.공시 • Jun 08Gerresheimer AG Announces Dividend for the Financial Year 2022, Payable on June 12, 2023Gerresheimer AG announced a dividend of EUR 1.25 for the financial year 2022. The dividend is to be paid out on June 12, 2023.공시 • Dec 28+ 1 more updateGerresheimer AG to Report Q3, 2023 Results on Oct 05, 2023Gerresheimer AG announced that they will report Q3, 2023 results on Oct 05, 2023공시 • Jul 13Gerresheimer AG to Report First Half, 2023 Results on Jul 06, 2023Gerresheimer AG announced that they will report first half, 2023 results on Jul 06, 2023이익 및 매출 성장 예측OTCPK:GRRM.Y - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수11/30/20282,683111N/A368611/30/20272,49685553421211/30/20262,35857383021111/30/20252,3093-80209128/31/20252,25023-439254N/A5/31/20252,18863-468239N/A2/28/20252,09079-549185N/A11/30/20242,036110-130240N/A8/31/20242,012114-131256N/A5/31/20242,002115-54344N/A2/29/20241,999117-15371N/A11/30/20231,990116-44294N/A8/31/20231,974107-27287N/A5/31/20231,959107-80205N/A2/28/20231,90497-89171N/A11/30/20221,81796-38222N/A8/31/20221,72591-45214N/A5/31/20221,63482-20225N/A2/28/20221,566854238N/A11/30/20211,498846212N/A8/31/20211,465861203N/A5/31/20211,43293-13182N/A2/28/20211,4189462243N/A11/30/20201,4198948222N/A8/31/20201,385-2553235N/A5/31/20201,394-3226208N/A2/29/20201,388-14-16165N/A11/30/20191,3928128193N/A8/31/20191,4152072161N/A5/31/20191,410207N/A183N/A2/28/20191,386179N/A159N/A11/30/20181,368129N/A173N/A8/31/20181,351124N/A184N/A5/31/20181,329131N/A192N/A2/28/20181,336137N/A206N/A11/30/20171,348101N/A219N/A8/31/20171,33149N/A184N/A5/31/20171,35053N/A176N/A2/28/20171,35856N/A190N/A11/30/20161,37558N/A173N/A8/31/20161,299118N/A195N/A5/31/20161,292106N/A201N/A2/29/20161,30199N/A188N/A11/30/20151,28396N/A204N/A8/31/20151,33569N/A206N/A5/31/20151,31569N/A173N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: GRRM.Y 의 연간 예상 수익 증가율(42.7%)이 saving rate(3.5%)보다 높습니다.수익 vs 시장: GRRM.Y 의 연간 수익(42.7%)이 US 시장(16.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: GRRM.Y 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: GRRM.Y 의 수익(연간 5.2%)이 US 시장(연간 11.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: GRRM.Y 의 수익(연간 5.2%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: GRRM.Y의 자본 수익률은 3년 후 7.7%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/18 22:34종가2026/05/05 00:00수익2025/08/31연간 수익2024/11/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Gerresheimer AG는 34명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Jonathon UnwinBarclaysPallav MittalBarclaysGaurav JainBarclays31명의 분석가 더 보기
공시 • Jul 11Gerresheimer AG Provides Revenue Guidance for the Second Half of 2025Gerresheimer AG provided revenue guidance for the second half of 2025. In the second half of 2025, Gerresheimer expects stronger growth again based on production ramp-ups and a good order intake, and anticipates organic revenue growth of 0 – 2% compared to the previous year.
공시 • Jun 05+ 1 more updateGerresheimer AG Revises Earnings Guidance for the Financial Year 2025Gerresheimer AG revised earnings guidance for the financial year 2025. For the financial year, the company expects organic revenue growth to be 1% to 2% compared to the previous year (previously: 3% to 5%).
공시 • Apr 11Gerresheimer AG Confirms Earnings Guidance for the Mid-Term of the Fiscal Year 2025Gerresheimer AG confirmed earnings guidance for the mid-term of the fiscal year 2025. For the mid-term, the company expects organic revenue growth 8% - 10% CAGR.
공시 • Apr 11Gerresheimer AG Provides Earnings Guidance for the Year 2024 and 2025Gerresheimer AG provided earnings guidance for the year 2024 and 2025. For the year 2024, the company expects revenue growth of 5% to 10%.For the year 2025, the company expects revenue growth of 10% to 15%.
공시 • Oct 06Gerresheimer AG Provides Earnings Guidance for Full Year 2023Gerresheimer AG provided earnings guidance for full year 2023. For the year, the company expects Organic revenue growth: at least 10% and Medium-term guidance (for group level, currency-adjusted), Organic revenue growth: at least 10%.
공시 • Jul 06Gerresheimer Ag Provides Revenue Guidance for Full Year 2023Gerresheimer AG provided revenue guidance for full year 2023. For the year, the company expects Organic revenue growth: at least 10% and Medium-term guidance (for group level, currency-adjusted), Organic revenue growth: at least 10%.
공시 • Apr 11Gerresheimer AG(XTRA:GXI) dropped from Germany SDAX (Total Return) IndexGerresheimer AG has been dropped from the Germany SDAX (Total Return) Index
공시 • Nov 22Gerresheimer AG Announces Supervisory Board ChangesKlaus Röhrig, co-founder and Co-Chief Investment Officer of the Active Ownership Group, has been appointed to the Supervisory Board of Gerresheimer AG until the next Annual General Meeting in June 2026. He succeeds Dr. Dorothea Wenzel, who made her position available to reflect the changed shareholder structure of the company in the composition of the Supervisory Board. With his appointment, Klaus Röhrig also assumes the duties of Dr. Dorothea Wenzel on the Audit Committee of Gerresheimer AG. Klaus Röhrig will stand for election to the Supervisory Board at the next Annual General Meeting on June 3, 2026. In total, four shareholder representatives will be up for election at the next Annual General Meeting of Gerresheimer AG’s co-determined Supervisory Board.
공시 • Oct 16+ 3 more updatesGerresheimer AG to Report Fiscal Year 2025 Results on Feb 26, 2026Gerresheimer AG announced that they will report fiscal year 2025 results at 1:25 PM, Central European Standard Time on Feb 26, 2026
공시 • Oct 14Gerresheimer Ag Announces Fda Grants Approval of Sq Innovation's Lasix®? OnyuGerresheimer announced that the US Food and Drug Administration (FDA) granted SQ Innovation approval for Lasix ONYU for treatment of edema in congestive heart failure. Lasix ONYU is a combination product consisting of a novel high-concentration formulation of the diuretic furosemide and the Gerresheimer on-body drug delivery device (infusor). It was developed to enable subcutaneous infusion of furosemide at home for selected patients, as prescribed by a clinician without the need for a healthcare professional to administer the drug. The cartridge-based infusor was designed and developed by Gerresheimer based on its proprietary infusor platform for subcutaneous drug delivery. Gerresheimer also manages production of the device as a full-service solution provider. First products of Lasix ONYU are expected to be available on the market already in 2025. The FDA's approval of the combination product demonstrates Gerresheimer's innovative strength and its strong partnership with customers, from product design to large-scale manufacturing. Device based on Gerresheimer's innovative micropump technology: The cartridge-based infus or was designed and developed by Ger Resheimer based on its proprietary infUSor platform for subcutaneous Drug delivery. The core technology is an innovative micropump which enables controlled, precise administration of a drug product according to a defined therapy regimen. Designed with patient comfort and the environment in mind The lightweight, compact device is patched onto the patient's body, making it comfortable for the patient to wear while the drug is gently infused. The reusable component, which is rated for delivery of 48 treatments with diuretic furosemides, is recyclable. Because only the disposable unit requires sterilization, radiation can be used instead of chemical sterilization, and no electronic components end up in medical waste. This two-component concept was developed in line with Gerresheimer's EcoDesign principles, which aim to increase product lifespan and reduce waste. Reducing total cost of care and improving patients' quality of life. The combination product Lasix ONYU also opens up possibilities to reduce the total cost of care. The two-component design results in a lower cost per treatment, because only the disposable part of the device needs to be replaced. Most importantly, the infusor allows for home treatment, reducing the length of hospital stay or avoiding the need for hospitalization for intravenous diuretic administration altogether. First products expected to be available already in 2025 In addition to Gerresheimer's role in design and development, Gerresheimer also manages production the device as a full- service solution provider. The disposable unit for the infusor is, for example, produced at the Gerresheimer facility in Wackersdorf, Germany, on a high-capacity semi-automated line. Production commenced earlier this year in anticipation of approval and first products are expected to be available before the end of the year.
공시 • Oct 10+ 2 more updatesGerresheimer AG Appoints Hans-Norbert Topp as Head of Combined Moulded Glass Business UnitGerresheimer AG announced that as part of the integration of Bormioli Pharma into the Gerresheimer Group, Gerresheimer has already begun to establish the combined Moulded Glass business as a global, independent unit. Hans-Norbert Topp, an internationally experienced manager with a proven track record, has been appointed to head the business unit.
공시 • Aug 22Active Ownership Wants Review at Gerresheimer After Taking StakeOn August 21, 2025, Active Ownership announced that it saw major potential for value creation at Gerresheimer AG and called for a strategic review. Active Ownership expressly welcomes the planned sale process for the moulded glass division and calls for a swift settlement in order to strengthen the Company's cash flow and reduce debt. Active Ownership also stated that further key measures should include additional portfolio optimization and the implementation of an efficiency programme, particularly through cost reductions in administration and business units. Active Ownership added that this would improve the return on the Company's sales by five percentage points, while also calling for the creation of a strategy committee to review all of the Company's ongoing projects.
공시 • Jul 11Gerresheimer AG Provides Revenue Guidance for the Second Half of 2025Gerresheimer AG provided revenue guidance for the second half of 2025. In the second half of 2025, Gerresheimer expects stronger growth again based on production ramp-ups and a good order intake, and anticipates organic revenue growth of 0 – 2% compared to the previous year.
공시 • Jun 06Asset Value Investors Calls for Changes at Gerresheimer AGOn June 5, 2025, Asset Value Investors Limited called upon Gerresheimer AG to take steps to restore its market value, a move partially supported by another top 30 investor. Asset Value Investors expressed its views that new financial leadership is needed to restore the Company's relationship and credibility with investors, it said in an open letter to the Company. Asset Value Investors also urged the Company to establish a capital allocation committee and exit its moulded glass business as soon as possible. Union Investment, which holds a 0.9% stake in the Company, said it backed the calls for new leadership and a sale of the moulded glass business but did not see a need for a capital allocation committee.
공시 • Jun 05+ 1 more updateGerresheimer AG Revises Earnings Guidance for the Financial Year 2025Gerresheimer AG revised earnings guidance for the financial year 2025. For the financial year, the company expects organic revenue growth to be 1% to 2% compared to the previous year (previously: 3% to 5%).
공시 • Apr 24Gerresheimer AG, Annual General Meeting, Jun 05, 2025Gerresheimer AG, Annual General Meeting, Jun 05, 2025, at 10:00 W. Europe Standard Time.
공시 • Apr 11Gerresheimer AG Confirms Earnings Guidance for the Mid-Term of the Fiscal Year 2025Gerresheimer AG confirmed earnings guidance for the mid-term of the fiscal year 2025. For the mid-term, the company expects organic revenue growth 8% - 10% CAGR.
공시 • Mar 13Warburg Pincus, KKR Consortium Reportedly in Talks to Buy GerresheimerA consortium consisting of Warburg Pincus LLC and KKR & Co. Inc. (NYSE:KKR) are in talks to acquire Gerresheimer AG (ETR:GXI), the German maker of packaging for drugs and cosmetics, according to people familiar with the matter. The private equity firms emerged as the frontrunner after they teamed up and other potential bidders including Bain Capital dropped, the people said, asking not to be identified discussing confidential information. The Warburg Pincus-KKR consortium is unlikely to offer a significant premium to Gerresheimer’s current price and there are still major hurdles to a deal, some of the people said. While the talks are advanced, any final agreement could take weeks and a deal could still fall apart, they added. Representatives for Gerresheimer, Warburg Pincus, KKR and Bain declined to comment.
공시 • Feb 27Gerresheimer AG announces Annual dividend, payable on June 10, 2025Gerresheimer AG announced Annual dividend of EUR 1.2500 per share payable on June 10, 2025, ex-date on June 06, 2025 and record date on June 09, 2025.
공시 • Feb 21Phillips-Medisize, Bain Capital Reportedly Eye GerresheimerUS medical solutions company Phillips-Medisize (Phillips-Medisize, LLC) and buyout firm Bain Capital (Bain Capital, LP) are among potential bidders for Gerresheimer AG (XTRA:GXI), the German maker of packaging for drugs and cosmetics, according to people familiar with the matter. The firms join other suitors that have been evaluating possible offers for part or all of Gerresheimer, the people said, asking not to be identified because the information is private.
공시 • Feb 20Gerresheimer AG to Report Q3, 2025 Results on Oct 10, 2025Gerresheimer AG announced that they will report Q3, 2025 results on Oct 10, 2025
공시 • Feb 11Gerresheimer Discussing Takeover with Private Equity InvestorsGerman pill bottles and syringes maker Gerresheimer AG (XTRA:GXI) said on February 07, 2025 that it is in early-stage talks with private equity investors over a potential takeover, confirming a media report. The private equity firms have expressed, on an informal and non-binding basis, their interest to explore a possible public takeover offer for Gerresheimer, the company said. The discussions are still in a very preliminary stage and it is not certain at this point whether an offer will actually be made, the firm added, without disclosing further details. The statement was made after news agency Bloomberg previously reported that private equity firms Warburg Pincus LLC, EQT AB (publ) (OM:EQT) and KKR & Co. Inc. (NYSE:KKR) among other suitors have shown interest in the German pill bottles and syringes maker.
공시 • Apr 11Gerresheimer AG Provides Earnings Guidance for the Year 2024 and 2025Gerresheimer AG provided earnings guidance for the year 2024 and 2025. For the year 2024, the company expects revenue growth of 5% to 10%.For the year 2025, the company expects revenue growth of 10% to 15%.
공시 • Dec 06+ 1 more updateGerresheimer AG, Annual General Meeting, Jun 05, 2024Gerresheimer AG, Annual General Meeting, Jun 05, 2024.
공시 • Oct 06Gerresheimer AG Provides Earnings Guidance for Full Year 2023Gerresheimer AG provided earnings guidance for full year 2023. For the year, the company expects Organic revenue growth: at least 10% and Medium-term guidance (for group level, currency-adjusted), Organic revenue growth: at least 10%.
공시 • Sep 28+ 2 more updatesGerresheimer AG to Report Q2, 2024 Results on Jul 11, 2024Gerresheimer AG announced that they will report Q2, 2024 results on Jul 11, 2024
공시 • Jul 06Gerresheimer Ag Provides Revenue Guidance for Full Year 2023Gerresheimer AG provided revenue guidance for full year 2023. For the year, the company expects Organic revenue growth: at least 10% and Medium-term guidance (for group level, currency-adjusted), Organic revenue growth: at least 10%.
공시 • Jun 08Gerresheimer AG Announces Dividend for the Financial Year 2022, Payable on June 12, 2023Gerresheimer AG announced a dividend of EUR 1.25 for the financial year 2022. The dividend is to be paid out on June 12, 2023.
공시 • Dec 28+ 1 more updateGerresheimer AG to Report Q3, 2023 Results on Oct 05, 2023Gerresheimer AG announced that they will report Q3, 2023 results on Oct 05, 2023
공시 • Jul 13Gerresheimer AG to Report First Half, 2023 Results on Jul 06, 2023Gerresheimer AG announced that they will report first half, 2023 results on Jul 06, 2023